Lexaria Bioscience (Lexaria Bioscience) Growth Rank : 1 (As of Apr. 30, 2024)

View and export this data going back to 2006. Start your Free Trial

What is Lexaria Bioscience Growth Rank?

Lexaria Bioscience has the Growth Rank of 1.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Competitive Comparison of Lexaria Bioscience's Growth Rank

For the Biotechnology subindustry, Lexaria Bioscience's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lexaria Bioscience's Growth Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lexaria Bioscience's Growth Rank distribution charts can be found below:

* The bar in red indicates where Lexaria Bioscience's Growth Rank falls into.

Lexaria Bioscience Growth Rank Related Terms

Thank you for viewing the detailed overview of Lexaria Bioscience's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Lexaria Bioscience (Lexaria Bioscience) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lexaria Bioscience Corp (NAS:LEXX) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

740 McCurdy Road, Suite 100, Kelowna, BC, CAN, V1X 2P7

Website

https://www.lexariabioscience.com

Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH has the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. The Company has four reportable segments: Intellectual Property Licensing, B2B Production, Research and Development and Corporate. It earns maximum revenue from Intellectual Property Licensing.

Executives

Catherine C. Turkel	director	19900 MACARTHUR BLVD., SUITE 550, IRVINE CA 92612
Gregory Downey	officer: Chief Financial Officer	100 - 740 MCCURDY ROAD, KELOWNA A1 V1X 2P7
Christopher Bunka	director, 10 percent owner, officer: CEO	1924 BIRKDALE AVE, KELOWNA A1 V1P1R7
Vanessa Carle	officer: Secretary	100 - 740 MCCURDY ROAD, KELOWNA A1 V1X 2P7
Reese Albert L Jr	director
Brian W. Quigley	director	100 740 MCCURDY ROAD, KELOWNA A1 23230
William Edward Mckechnie	director	305 MARGARET AVENUE, KITCHENER A6 N2H 6S4
Allan Horst Spissinger	officer: CFO	8131 198A STREET, LANGLEY A1 V2Y 1Y6
John Martin Docherty	director, 10 percent owner	23 MIKELEN DRIVE, PORT PERRY A6 L9L 1V1
Baljinder Bhullar	director, officer: CFO	604 - 700 WEST PENDER, VANCOUVER A1 V6C 1G8
Nicholas W Baxter	director	220 SPRINGFIELD ROAD, ABERDEEN, ABERDEENSHIRE, SCOTLAND X0 AB15 6AU
Dustin Arthur Elford	director	888 - 609 WEST HASTINGS STREET, VANCOUVER A1 V6B 4W4
Thomas James Ihrke	officer: Sr. VP, Business Development	38 KRIER LANE, MOUNT PLEASANT SC 29464
David Demartini	director, 10 percent owner	11714 SPRIGGS WAY, HOUSTON TX 77024
Leonard Macmillan	director, officer: Vice President - Corp Develop	SUITE 302, 125A - 1030 DENMAN STREET, VANCOUVER A1 V6G 2M6